Oncology Medical News about pegylated-asparaginase

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A population pharmacokinetic model for pegylated-asparaginase in children
British Journal of Haematology, 10/16/09

Hempel G et al. – A subgroup of the patients showed a high clearance, probably due to the development of inactivating antibodies. This is the first model able to predict the activity–time course of PEG–asparaginase at different dosing levels and can therefore be used for developing new dosing regimens.

<< Previous
Lymphoma cell VEGFR2 expression detected by immunohistochemistry...

Next >>
Risk of progression in smouldering myeloma and monoclonal...